Winnipeg Free Press

Winnipeg Free Press (Newspaper) - January 23, 2015, Winnipeg, Manitoba C M Y K PAGE A10 A 10 WINNIPEG FREE PRESS, FRIDAY, JANUARY 23, 2015 CANADA / WORLD winnipegfreepress. com Visit us at www. gauthierchrysler. com 1- 877- 585- 8329 . 204- 661- 8999 137 5 R EGENT A V ENUE * Payments are based on 3.99- 4.99% interest 72- 96 months OAC. Ask dealer for details. All payments are plus taxes and fees. GAUTHIER CHRYSLER DODGE JEEP RAM R10410 $ 33,995 $ 198 B / W 2014 RAM 1500 QUAD CAB SLT NEXT TO CLUB REGENT CASINO! A10313 $ 34,995 $ 205 B / W 2014 DODGE CHARGER SXT AWD WHITE GE R10266 $ 28,987 $ 169 B / W 2014 DODGE RAM 1500 SLT QUAD CAB QUAD CAB H1498A $ 24,995 $ 163 B / W 2013 CHEVROLET SILVERADO 1500 WORK TRUCK CREW CAB R10171 $ 27,739 $ 181 B / W 2013 DODGE RAM 1500 SLT QUAD CAB R10272 $ 14,995 $ 98 B / W 2013 CHRYSLER 200 TOURING SEDAN YSLER R10276 $ 25,995 $ 193 B / W 2011 DODGE RAM 1500 ST QUAD CAB QUAD CAB H1949A $ 28,995 $ 189 B / W 2012 FORD F- 150 SUPER CREW H2177A $ 38,995 $ 228 B / W 2014 TOYOTA HIGHLANDER LE WHITE $ 32,995 32,995 $ 199 199 B / W 2014 DODGE CHARGER SXT PLUS A WD R10412 $ 32,995 $ 193 B / W 2014 RAM 1500 SLT QUAD CAB SILVER 500 H730A $ 34,266 $ 255 B / W 2011 JEEP GRAND CHEROKEE LIMITED SPORT UTILITY R10007 $ 24,407 $ 159 B / W 2013 DODGE RAM 1500 ST QUAD CAB QUAD CAB R10438 $ 32,995 $ 194 B / W 2014 RAM 1500 QUAD CAB SLT R10230A $ 32,995 $ 215 B / W 2012 CADILLAC CTS BASE COUPE A10207 $ 24,995 $ 163 B / W 2013 CHRYSLER TOWN & COUNTRY TOURING PASSENGER VAN URIN G A10318 $ 34,995 $ 205 B / W 2014 CHRYSLER TOWN & COUNTRY TOURING LEATHER R ING R10292 $ 34,995 $ 208 B / W 2014 JEEP WRANGLER UNLIMITED SAHA RA H1705A $ 22,188 $ 145 B / W 2013 CHEVROLET SILVERADO 1500 LS T H A N K Y O U MA N I TO B A F O R M A K I N G U S T HE N UM B E R O N E V O L U M E C H R Y S L ER DE A L E R I N T H E P R A I R I E S ! A10453 R10365 $ 47,995 $ 278 B / W 2014 DODGE DURANGO LIMITED 4098A $ 21,995 $ 144 B / W 2013 DODGE AVENGER SXT H1672A $ 7,485 $ 111 B / W 2007 CHEVROLET COBALT SS COUPE H1190A $ 14,995 $ 134 B / W 2009 CHRYSLER 300 LIMITED SEDAN H1890A $ 17,995 $ 102 B / W 2014 DODGE GRAND CARAVAN SE BILLET METALLIC H2169A $ 29,500 W AS $ 32,995 2012 DODGE DURANGO DURANGO HEAT BLACK URANGO R10261 $ 26,995 $ 160 B / W 2014 JEEP COMPASS LIMITED 4X4 BLACK A10451 H1855A $ 20,880 $ 138 B / W 2012 DODGE GRAND CARAVAN SE/ SXT PASSENGER VAN / H1230A $ 36,995 $ 241 B / W 2012 JEEP GRAND CHEROKEE OVERLAND SPORT UTILITY R10289 $ 27,994 $ 183 B / W 2013 DODGE RAM 1500 ST CREW CAB CREW CAB R10291 $ 37,776 $ 247 B / W 2012 JEEP GRAND CHEROKEE OVERLAND SPORT UTILITY R10281 $ 23,670 $ 139 B / W 2014 CHRYSLER TOWN & COUNTRY TOURING PASSENGER VAN R10292 $ 19,995 $ 117 B / W 2014 DODGE GRAND CARAVAN SE/ SXT PASSENGER VAN / R10347 $ 36,995 $ 216 B / W 2014 JEEP WRANGLER UNLIMITED SAHARA BLACK H1634A $ 23,516 $ 137 B / W 2014 JEEP CHEROKEE SPORT R10352 $ 32,995 $ 193 B / W 2014 DODGE GRAND CARAVAN EXPRESS RAND ES S H1626A $ 18,083 $ 118 B / W 2012 DODGE GRAND CARAVAN SE/ SXT PASSENGER VAN H1088A $ 19,995 $ 118 B / W 2014 CHEVROLET CRUZE $ 32,995 32,995 $ 199 B / W 2014 CHRYSLER 300 TOURING A W D D T ORONTO - Clinical trials designed to show whether two Ebola vaccines and the Ebola therapy ZMapp actually work will begin within the next two to three weeks, American officials designing the studies said Thursday. But falling case counts in the three West African countries where the outbreak has raged are forcing some modification of the vaccine trial designs - and potentially lowering expectations of what they will be able to achieve, the officials acknowledged. The largest of the planned vaccine trials - expected to begin within the next two weeks in Liberia - may be expanded into Sierra Leone, said Dr. Anthony Fauci, director of the U. S. National Institute of Allergy and Infectious Diseases. Fauci, whose agency will run this trial in conjunction with the Liberian government, said the change would have to be approved by the governments of Liberia and Sierra Leone. But he said representatives of the two countries proposed the idea at a recent planning meeting. With the marked decline in new cases, it could take between nine and 12 months to run this trial, Fauci said. And he acknowledged there is a possibility it will not show whether one or both Ebola vaccines to be tested actually work. Still, data that the trial generates could be used to get one or both vaccines licensed through a different regulatory approach known as the animal rule. Some of the 27,000 people to be enrolled will give blood samples that scientists will be able to study to see if the vaccines triggered production of antibodies to Ebola. In special circumstances where it isn't possible to test vaccines or drugs in the standard way, the U. S. Food and Drug Administration has a rule that allows effectiveness data generated in two different animal models to be used as a stand- in for data in humans. But that could be a longer and more difficult road to licensure for the vaccines. " You could carry out the trial, not prove efficacy, but get enough safety and immunogenicity data to allow for an alternative regulatory approval such as by the animal rule," Fauci said. The Liberian trial will test the two most advanced Ebola vaccines, one made by British pharma giant GSK, the other by NewLink Genetics and Merck. The GSK vaccine was designed by scientists at the National Institute of Allergy and Infectious Diseases while the NewLink- Merck vaccine was created by researchers at Canada's National Microbiology Laboratory in Winnipeg. Healthy volunteers will be randomly assigned to receive one of the vaccines or a placebo injection. If one or both of the vaccines is protective, you would expect to see far fewer infections in the weeks and months after vaccination in people who received one of the vaccines. But if Ebola transmission in Liberia sinks to very low levels, it may be impossible to tell if the vaccines work. If no one is getting sick, you have no proof the vaccines are protective. Data released Wednesday by the World Health Organization showed that in the 21 days prior to Jan. 18 there were only 25 confirmed, probable or suspected Ebola cases in Liberia. It is conceivable there might be an answer sooner to the question of whether ZMapp works. The treatment is a hybrid of two antibody cocktails produced by teams in Winnipeg and at the National Institute of Allergy and Infectious Diseases. The Winnipeg lab did the work to determine the optimal mix of antibodies, eventually hitting on two created in Winnipeg and one made at the NIAID. A number of people have been treated with ZMapp since last summer, and several have made rapid recoveries. But treatment was not used in a clinical trial setting, so it's impossible to credit the antibody cocktail with those recoveries. The ZMapp clinical trial, which will take place in Liberia and the United States - if the country has more cases - will randomly assign people diagnosed with Ebola to receive standard care, or standard care plus ZMapp. Fauci said that the statistical projections suggest that it could take as few as 12 patients - or as many as 40 - to determine if the treatment is effective. FDA approval of this trial is expected soon and the trial will start in two or three weeks after that, he said. - The Canadian Press By Helen Branswell Ebola vaccine clinical trials to begin The Liberian trial will test the two most advanced Ebola vaccines. The NewLink- Merck vaccine was created by researchers at the National Microbiology Laboratory in Winnipeg. The GSK vaccine was created by scientists at the National Institute of Allergy and Infectious Diseases. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES / THE ASSOCIATED PRESS ARCHIVES A_ 12_ Jan- 23- 15_ FP_ 01. indd A10 1/ 22/ 15 9: 16: 37 PM ;